In 2019, ASCO recognizes the progress in treating rare cancers as the Advance of the Year. Impressive progress has been made in bringing new treatment advances to cancers that are rare and difficult to treat. This year’s Clinical Cancer Advances report describes emerging treatments for thyroid cancer, uterine cancer, desmoid tumor, neuroendocrine tumor, and tenosynovial giant cell tumor.
In this podcast, Cancer.Net Associate Editor Dr. Lynn Henry describes a clinical trial that studied a new approach to treating HER2-positive breast cancer.
Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.
Kidney cancer is the sixth most common cancer for men and the tenth most common cancer for women. Cancer.Net Associate Editor Brian Rini, MD, shares 4 things people need to know about kidney cancer.
Lung cancer affects tens of thousands of Americans every year. In this blog post, Cancer.Net Associate Editor Dr. Jyoti Patel describes 9 things every person should know about lung cancer.
In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
Identifying genetic changes has given us new insights in early detection and treatment of advanced and castration-resistant prostate cancer.
The Targeted Agent and Profiling Utilization Registry (TAPUR) study is ASCO’s first clinical trial. In this podcast, ASCO Chief Medical Officer Dr. Richard Schilsky discusses TAPUR and why it is important to patients and the medical community.